Stakeholder Opinions - Non-hormonal Treatments for Menopausal Symptoms
Stakeholder Opinions - Non-hormonal Treatments for Menopausal Symptoms - companiesandmarkets.com adds new report
© companiesandmarkets.com
19.11.2008 18:32:02 Stakeholder Opinions - Non-hormonal Treatments for Menopausal Symptoms - a new market research report on www.companiesandmarkets.com
(live-PR.com) - www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highly efficacious. However, concerns surrounding the safety of HRT have led to an increase in demand for non-hormonal alternatives.
Scope
Overview of menopause,
including a review of the prevalence of vasomotor symptoms to better understand the size of the target patient population.
Summary of topical issues in the treatment of menopausal symptoms and rationale for a non-hormonal approach treatment.
Review of pipeline non-hormonal drugs and analysis of their future potential in relation to currently available hormone replacement therapy.
Insight from interviews with seven key international experts in the field of menopause and associated treatments
Highlights
The key opportunity for non-hormonal treatments lies in capturing sales that have been lost by the hormonal treatments since the WHI results. Despite increased demand, the current R&D pipeline for non-hormonals is small and lacks innovation. Wyeth´s Pristiq could be first to market although regulatory delays indicate possible non-approval.
Returning confidence in HRT among gynecologists and the recent upturn in sales of these therapies represents a growing barrier to entry for non-hormonal drug companies. Nevertheless, prevailing mistrust of HRT among primary care physicians (PCPs) and eligible patients represents a key market opportunity for non-hormonals.
In view of the lower efficacy of non-hormonals compared to HRT, it is expected that uptake will be strongest among patient groups for whom HRT is contraindicated, as well as highly symptomatic patients who do not wish to receive HRT due to safety concerns. Mildly symptomatic patients also represent a key target group.
Reasons to Purchase
Understand key opinion leaders views on topical issues in the current and future treatment of menopausal symptoms.
Explore the R&D pipeline for non-hormonals and the future directions of the market as identified by interviewed KOLs.
Identify the drivers and resistors for key non-hormonal drug treatments in the market.
www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highly efficacious. However, concerns surrounding the safety of HRT have led to an increase in demand for non-hormonal alternatives.
Scope
Overview of menopause,
|
|
Summary of topical issues in the treatment of menopausal symptoms and rationale for a non-hormonal approach treatment.
Review of pipeline non-hormonal drugs and analysis of their future potential in relation to currently available hormone replacement therapy.
Insight from interviews with seven key international experts in the field of menopause and associated treatments
Highlights
The key opportunity for non-hormonal treatments lies in capturing sales that have been lost by the hormonal treatments since the WHI results. Despite increased demand, the current R&D pipeline for non-hormonals is small and lacks innovation. Wyeth´s Pristiq could be first to market although regulatory delays indicate possible non-approval.
Returning confidence in HRT among gynecologists and the recent upturn in sales of these therapies represents a growing barrier to entry for non-hormonal drug companies. Nevertheless, prevailing mistrust of HRT among primary care physicians (PCPs) and eligible patients represents a key market opportunity for non-hormonals.
In view of the lower efficacy of non-hormonals compared to HRT, it is expected that uptake will be strongest among patient groups for whom HRT is contraindicated, as well as highly symptomatic patients who do not wish to receive HRT due to safety concerns. Mildly symptomatic patients also represent a key target group.
Reasons to Purchase
Understand key opinion leaders views on topical issues in the current and future treatment of menopausal symptoms.
Explore the R&D pipeline for non-hormonals and the future directions of the market as identified by interviewed KOLs.
Identify the drivers and resistors for key non-hormonal drug treatments in the market.
www.companiesandmarkets.com/Summary-Market-Repor ..
| Author: |
